D Theodorescu

Summary

Affiliation: University of Virginia
Country: USA

Publications

  1. ncbi When is a negative lymph node really negative? Molecular tools for the detection of lymph node metastasis from urological cancer
    Dan Theodorescu
    Department of Urology, Molecular Physiology, University of Virginia Health System, Charlottesville, VA 22908-0422, USA
    Urol Oncol 22:256-9. 2004
  2. ncbi Unusual case of non-exophytic invasive penile squamous cell cancer arising from a chronic sinus tract
    S R Broder
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville 22908, USA
    Scand J Urol Nephrol 33:333-5. 1999
  3. ncbi A prospective pilot evaluation of urinary and immunohistochemical markers as predictors of clinical stage of urothelial carcinoma of the bladder
    T Krupski
    Departments of Urology, Pathology and Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    BJU Int 85:1027-32. 2000
  4. ncbi Prostatourethral-rectal fistula after prostate brachytherapy
    D Theodorescu
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Cancer 89:2085-91. 2000
  5. ncbi Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine
    Dan Theodorescu
    Paul Mellon Prostate Cancer Institute, University of Virginia, Charlottesville, VA 22908, USA
    Electrophoresis 26:2797-808. 2005
  6. ncbi The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells
    T Krupski
    Department of Molecular Physiology and Biological Physics, University of Virginia, Health Sciences Center, Charlottesville, USA
    Growth Factors 18:287-302. 2001
  7. ncbi Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors
    Z Wu
    Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia, USA
    Prostate 68:935-44. 2008
  8. ncbi Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration
    Y Wu
    Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA
    Oncogene 27:6679-89. 2008
  9. ncbi Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia
    Y Wu
    Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA, USA
    Oncogene 26:765-73. 2007
  10. ncbi RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation
    Michael A Harding
    Department of Urology, University of Virginia, Charlottesville, VA 22908, USA
    Urol Oncol 25:401-6. 2007

Detail Information

Publications105 found, 100 shown here

  1. ncbi When is a negative lymph node really negative? Molecular tools for the detection of lymph node metastasis from urological cancer
    Dan Theodorescu
    Department of Urology, Molecular Physiology, University of Virginia Health System, Charlottesville, VA 22908-0422, USA
    Urol Oncol 22:256-9. 2004
  2. ncbi Unusual case of non-exophytic invasive penile squamous cell cancer arising from a chronic sinus tract
    S R Broder
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville 22908, USA
    Scand J Urol Nephrol 33:333-5. 1999
    ..Finally, this case demonstrates the key diagnostic utility of deep core biopsies of the penis in situations where a cutaneous lesion does not exist...
  3. ncbi A prospective pilot evaluation of urinary and immunohistochemical markers as predictors of clinical stage of urothelial carcinoma of the bladder
    T Krupski
    Departments of Urology, Pathology and Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    BJU Int 85:1027-32. 2000
    ....
  4. ncbi Prostatourethral-rectal fistula after prostate brachytherapy
    D Theodorescu
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Cancer 89:2085-91. 2000
    ..Thus, the authors sought to determine these factors in a large series of patients who were treated at two institutions...
  5. ncbi Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine
    Dan Theodorescu
    Paul Mellon Prostate Cancer Institute, University of Virginia, Charlottesville, VA 22908, USA
    Electrophoresis 26:2797-808. 2005
    ..In conclusion, this early pilot study suggests that CE-MS of urine warrants further investigation as a tool that can identify putative biomarkers for CaP...
  6. ncbi The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells
    T Krupski
    Department of Molecular Physiology and Biological Physics, University of Virginia, Health Sciences Center, Charlottesville, USA
    Growth Factors 18:287-302. 2001
    ..In addition, these results highlight the importance of the tumor microenvironment in determining the biological impact of transfected and overexpressed genes in the study of tumor biology...
  7. ncbi Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors
    Z Wu
    Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia, USA
    Prostate 68:935-44. 2008
    ..Although there are data implicating PI3K-Akt or MAPK pathway activation with resistance to EGFR inhibitors in CaP, the potential cross-talk between these pathways in response to EGFR or MAPK inhibitors remains to be examined...
  8. ncbi Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration
    Y Wu
    Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA
    Oncogene 27:6679-89. 2008
    ..These studies provide a general approach to identify the clinically relevant genes in cancer cell migration and mechanistically implicate two novel genes in this process in human bladder cancer...
  9. ncbi Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia
    Y Wu
    Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA, USA
    Oncogene 26:765-73. 2007
    ..In conclusion, NMU is a RhoGDI2-regulated gene that appears important for tumorigenicity, lung metastasis and cancer cachexia, and thus a promising therapeutic target in cancer...
  10. ncbi RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation
    Michael A Harding
    Department of Urology, University of Virginia, Charlottesville, VA 22908, USA
    Urol Oncol 25:401-6. 2007
    ..These targets, endothelin-1 and Neuromedin U are excellent potential targets for therapeutic intervention in the metastatic cascade...
  11. ncbi Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey
    Joshua D Hall
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Urology 61:402-7. 2003
    ..In addition, by examining post-treatment "surprises," our data will allow the development of improved educational approaches to aid decision making...
  12. ncbi Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy
    B R Fulmer
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Cancer 91:2046-55. 2001
    ..Initially RP patients demonstrated worse SF and SFB scores, but RP patients returned to HBTC levels within 18 months...
  13. ncbi Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells
    Peter C Black
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:1478-86. 2008
    ..The aim of this study was to define molecular markers of response to cetuximab therapy in a panel of urothelial carcinoma cell lines...
  14. ncbi Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer
    Hillary Copp
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Urology 65:1146-51. 2005
    ..2 ng/mL criterion. CONCLUSIONS: Trimodality RT offers excellent tumor control in patients with poor prognosis who often relapse early. Longer follow-up will be important to determine whether these results are durable over time...
  15. ncbi Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy
    Nicole Miller
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Cancer 103:2499-506. 2005
    ..A longer follow-up period will be needed to verify whether these are predictive of long-term cancer control...
  16. ncbi The role of PTEN in prostate cancer cell tropism to the bone micro-environment
    Z Wu
    Department of Molecular Physiology and Biological Physics, Box 422, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA
    Carcinogenesis 28:1393-400. 2007
    ..Our results support the notion that loss of PTEN function in human prostate cancer may specifically facilitate bone rather than other organ metastasis and suggest that Rac1, as a PTEN effector, may contribute to this metastatic tropism...
  17. ncbi Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression
    D Theodorescu
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville 22908, USA
    Int J Cancer 78:775-82. 1998
    ..Our results would seem to corroborate the notion that a high dietary intake of isoflavones is a likely explanation for the decreased incidence of invasive bladder cancer...
  18. ncbi Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells
    Z Wu
    Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Prostate 66:1114-23. 2006
    ..While the transcriptional activity of the androgen receptor (AR) is inhibited by PTEN in androgen sensitive prostate cancer (CaP), the role of PTEN in androgen disease is unclear...
  19. ncbi An 800-kb region of deletion at 13q14 in human prostate and other carcinomas
    C Chen
    Department of Pathology, University of Virginia Health System, Charlottesville, Virginia 22908, USA
    Genomics 77:135-44. 2001
    ..This study also provides a framework for the fine-mapping, cloning, and identification of a novel tumor-suppressor gene at 13q14...
  20. ncbi Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men
    E A Bissonette
    Department of Urology, Division of Biostatistics and Epidemiology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    J Urol 166:1328-31; discussion 1331-2. 2001
    ....
  21. ncbi Genoproteomic mining of urothelial cancer suggests {gamma}-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy
    COURTNEY POLLARD
    Department of Molecular Physiology, University of Virginia, Charlottesville, 22908, USA
    Am J Pathol 175:1824-30. 2009
    ..Although these predictive results were obtained on tumor tissues, the presence of GGH and DBI in urine serves as a rationale for developing them as urinary markers of clinical outcomes for patients treated with neoadjuvant MVAC...
  22. ncbi Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function
    Yimin Wu
    Department of Molecular Physiology, University of Virginia, Charlottesville, VA 22908, USA
    Proc Natl Acad Sci U S A 106:5807-12. 2009
    ..Our findings also suggest caution in using Src inhibitors in the hope of delaying progression in patients with bladder cancer...
  23. ncbi Molecular determination of perivesical and lymph node metastasis after radical cystectomy for urothelial carcinoma of the bladder
    M J Seraj
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Clin Cancer Res 7:1516-22. 2001
    ..Larger studies with 5-7-year follow-up will be required to determine the prognostic significance of such molecular information...
  24. ncbi Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma
    R J Santen
    Department of Medicine, University of Virginia Health System, Charlottesville, Virginia 22908, USA
    Cancer 92:2095-101. 2001
    ..Reports of androgen receptor mutations and historic clinical observations raised the hypothesis that estrogens might be involved in the proliferation of androgen-refractory prostate carcinoma...
  25. ncbi The role of SPARC in the TRAMP model of prostate carcinogenesis and progression
    N Said
    Department of Urology, University of Virginia, Charlottesville, VA 22908, USA
    Oncogene 28:3487-98. 2009
    ..Our findings demonstrate that both tumor and stromal SPARC are limiting for primary prostate tumorigenesis and progression, through effects on the cell cycle and the creation of a less favorable tumor microenvironment...
  26. ncbi Manipulation of gene expression by an ecdysone-inducible gene switch in tumor xenografts
    L R Karns
    1Upstate Biotechnology Inc, Charlottesville, Virginia, USA
    BMC Biotechnol 1:11. 2001
    ..The popularity of the ecdysone inducible gene switch system has led us to investigate whether such a system can successfully regulate gene expression in a syngeneic tumor system in vivo...
  27. ncbi Pathways of metastasis suppression in bladder cancer
    Neveen Said
    Department of Urology, University of Virginia, Box 800422, Charlottesville, VA 22908, USA
    Cancer Metastasis Rev 28:327-33. 2009
    ..In this review, we will discuss the established roles of c-Src and RhoGDI2 in bladder cancer and speculate on their therapeutic relevance...
  28. ncbi Prospective evaluation of the prognostic relevance of molecular staging for urothelial carcinoma
    Hillary L Copp
    Department of Urology, University of Virginia, Charlottesville, Virginia, USA
    Cancer 107:60-6. 2006
    ....
  29. ncbi RhoGDI2 is an invasion and metastasis suppressor gene in human cancer
    John J Gildea
    Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Cancer Res 62:6418-23. 2002
    ..These results indicate that RhoGDI2 is a metastasis suppressor gene, a marker of aggressive human cancer, and a promising target for therapy...
  30. ncbi Gene profiling and promoter reporter assays: novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action
    Dora Bigler
    Department of Molecular Physiology and Biological Physics and Cancer Center, University of Virginia, Health Sciences Center, Charlottesville, VA 22908, USA
    Oncogene 22:1261-72. 2003
    ....
  31. ncbi Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy
    Nicole L Miller
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville 22908, USA
    Cancer 97:1203-10. 2003
    ....
  32. ncbi Cell density mediated pericellular hypoxia leads to induction of HIF-1alpha via nitric oxide and Ras/MAP kinase mediated signaling pathways
    E A Sheta
    Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia, USA
    Oncogene 20:7624-34. 2001
    ..In addition, these results highlight the importance of examining pericellular hypoxia as a possible stimulus in experiments involving in vitro cell density manipulation even in routine normoxic culture conditions...
  33. ncbi Impact of second opinion pathology in the definitive management of patients with bladder carcinoma
    T R Coblentz
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia
    Cancer 91:1284-90. 2001
    ..CONCLUSIONS: The review of bladder pathologic materials before definitive therapy can impact clinical decisions significantly and can reduce overall expenditures for the management of this cohort of bladder carcinoma patients...
  34. ncbi Motivations and influences on the use of complementary medicine in patients with localized prostate cancer treated with curative intent: results of a pilot study
    J D Hall
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville 22908, USA
    BJU Int 91:603-7. 2003
    ..Interestingly, physicians were generally supportive of the use of such approaches...
  35. ncbi Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer
    Jae K Lee
    Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA
    Clin Cancer Res 16:711-8. 2010
    ..Our goal was to compare the performance of four conceptually different predictors in an independent cohort of patients...
  36. ncbi Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis
    Dan Theodorescu
    Department of Molecular Physiology, Mellon Prostate Cancer Institute, University of Virginia, Charlottesville, VA, USA
    Lancet Oncol 7:230-40. 2006
    ..We aimed to use mass spectrometry and bioinformatics to define and validate a cancer-specific proteomic pattern...
  37. ncbi Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination
    Steven Christopher Smith
    Department of Molecular Physiology and Biological Physics, University of Virginia Health System, Charlottesville, VA 22908, USA
    Am J Pathol 174:371-9. 2009
    ..In summary, LAMC2 is a novel biomarker of bladder cancer metastasis that reflects the propensity of cells to metastasize via either lymphatic or hematogenous routes...
  38. ncbi Integrin agonists as adjuvants in chemotherapy for melanoma
    Martin A Schwartz
    Department of Microbiology, Robert M Berne Cardiovascular Research Center, University of Virginia, 415 Lane Road, Charlottesville, VA 22908, USA
    Clin Cancer Res 14:6193-7. 2008
    ..Thus, reduced integrin-dependent adhesion to ECM could mediate therapy resistance. The goal of this study was to test whether stimulation of integrin signaling could increase chemotherapeutic efficacy...
  39. ncbi Atypical small acinar proliferation: biopsy artefact or distinct pathological entity?
    Sarah C Flury
    Department of Urology, University of Virginia Health System, Charlottesville, VA, USA
    BJU Int 99:780-5. 2007
    ....
  40. ncbi Complementary and alternative medicine modality use and beliefs among African American prostate cancer survivors
    Randy A Jones
    School of Nursing, University of Virginia, Charlottesville, VA, USA
    Oncol Nurs Forum 34:359-64. 2007
    ..To examine the cultural beliefs and attitudes of African American prostate cancer survivors regarding the use of complementary and alternative medicine (CAM) modalities...
  41. ncbi Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis
    Zhong Wu
    Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908, USA
    Neoplasia 11:66-76. 2009
    ..Our results suggest a hypothetical model whereby PTEN loss upregulates cell cycle genes such as cdc6 and cyclin E2 that in turn promote metastatic colonization at distant sites...
  42. ncbi Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis
    Behfar Ehdaie
    Department of Urology, Box 422, University of Virginia, Charlottesville, Virginia 22908, USA
    Expert Rev Anticancer Ther 8:1103-10. 2008
    ....
  43. ncbi Family interactions among African American prostate cancer survivors
    Randy A Jones
    School of Nursing, University of Virginia, Charlottesville, VA 22908, USA
    Fam Community Health 31:213-20. 2008
    ..Data analysis revealed that support from family members and friends plays an important role in how men cope with their treatment and recovery from prostate cancer...
  44. ncbi Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas
    Helen P Cathro
    Department of Pathology, University of Virginia Health System, Charlottesville, 22908, USA
    Cancer Immunol Immunother 59:465-72. 2010
    ..The goal of this study was to analyze protein expression of antigen processing machinery (APM) components in bladder carcinoma (BC), and to assess the clinical significance of defects in their expression...
  45. ncbi Invasion and metastasis models for studying RhoGDI2 in bladder cancer
    Matthew D Nitz
    Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia, USA
    Methods Enzymol 439:219-33. 2008
    ....
  46. ncbi RhoGDI signaling provides targets for cancer therapy
    Michael A Harding
    Department of Urology, University of Virginia, Charlottesville, Virginia, USA
    Eur J Cancer 46:1252-9. 2010
    ..Several novel therapeutic strategies are proposed for intervening in RhoGDI signaling, and potential complications arising from their implementation are discussed...
  47. ncbi A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery
    Jae K Lee
    Department of Public Health Sciences, University of Virginia, Charlottesville, VA 22908, USA
    Proc Natl Acad Sci U S A 104:13086-91. 2007
    ..Furthermore, we used COXEN for in silico screening of 45,545 compounds and identify an agent with activity against human bladder cancer...
  48. ncbi Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer
    Dmytro M Havaleshko
    Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908, USA
    Neoplasia 11:1185-93. 2009
    ..These results have significant implications for the use of such tools in personalizing the approach to cancers treated with EGFR-directed targeted therapies...
  49. ncbi Robot-assisted radical cystectomy in the management of bladder cancer
    Jessica L Keim
    Paul Mellon Prostate Cancer Institute and Department of Urology, University of Virginia Health Sciences Center, Charlottesville, VA, USA
    ScientificWorldJournal 6:2560-5. 2006
    ....
  50. ncbi Surgery or radiation: what is the optimal management for locally advanced prostate cancer?
    Sophie G Fletcher
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Can J Urol 12:58-61; discussion 101-2. 2005
    ..CONCLUSION: The optimal management for patients with locally advanced prostate cancer is unclear. While randomized clinical trials will eventually shed light on this question, interim solutions may provide some answers in the short term...
  51. ncbi The impact of prostate volume following neoadjuvant androgen deprivation on quality of life and voiding symptoms in patients undergoing permanent prostate brachytherapy
    Tracey Krupski
    Department of Urology, University of Virginia Health Sciences Center, Box 422, Charlottesville, VA 22908, USA
    Eur Urol 43:467-72. 2003
    ..We sought to determine if data from patients treated with neoadjuvant androgen ablation followed by BT at our institution supported this notion using a cross-sectional study design...
  52. ncbi Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer
    Dan Theodorescu
    Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Clin Cancer Res 10:3800-6. 2004
    ....
  53. ncbi Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling
    Michael A Harding
    Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia 22908, USA
    Cancer Res 62:6981-9. 2002
    ....
  54. ncbi Determinants of long-term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer
    Emily B Bradley
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908-0422, USA
    BJU Int 94:1003-9. 2004
    ..Men treated with BTC have a worse QoL...
  55. ncbi Angiogenesis in prostate cancer: biology and therapeutic opportunities
    B Nicholson
    Department of Urology, University of Virginia, Charlottesville 22908-0422, USA
    Cancer Metastasis Rev 20:297-319. 2001
    ..In this review we discuss the mediators of angiogenesis, the strategies for manipulating angiogenic factors, and possible therapeutic applications with a special emphasis on prostate cancer...
  56. ncbi Expression profiling of Ral-depleted bladder cancer cells identifies RREB-1 as a novel transcriptional Ral effector
    G Oxford
    Department of Molecular Physiology and Biological Physics, Health Sciences Center, University of Virginia, Charlottesville, VA 22908, USA
    Oncogene 26:7143-52. 2007
    ..Taken together, these data strongly suggest that Ral family members mediate both common and specific transcriptional programs that are associated with human cancer and identify RREB-1 as a novel transcriptional effector of Ral...
  57. ncbi Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2
    Brian Titus
    Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia 22908, USA
    Cancer Res 65:7320-7. 2005
    ..The data also suggest that blockade of the ET-1 axis may prevent lung metastasis, a new therapeutic concept that warrants clinical evaluation...
  58. ncbi Molecular credentialing of rodent bladder carcinogenesis models
    Paul D Williams
    Department of Public Health Sciences, Division of Biostatistics, University of Virginia School of Medicine, Charlottesville, VA 22908 0717, USA
    Neoplasia 10:838-46. 2008
    ..Finally, we provide a list of genes that are likely candidates for driving this disease process by virtue of their concordant regulation in tumors of all three species...
  59. ncbi Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas
    Christopher Y Thomas
    Department of Hematology and Oncology, UVA HSC, P.O. Box 800716, Charlottesville, VA 22908, USA
    World J Urol 24:565-78. 2006
  60. ncbi The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer
    Steven C Smith
    Department of Molecular Physiology, University of Virginia, Charlottesville, Virginia 22908, USA
    Cancer Res 70:1753-8. 2010
    ....
  61. ncbi Health-related quality of life after prostate brachytherapy
    Nicole L Miller
    Department of Urology, University of Virginia, Charlottesville, Virginia, USA
    BJU Int 94:487-91. 2004
  62. ncbi Perioperative costs and charges of prostate brachytherapy and prostatectomy
    Antoine A Makhlouf
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Urology 60:656-60. 2002
    ..Without a clear cost advantage of USBT over RP, the choice of therapy should continue to be primarily influenced by tumor characteristics, treatment efficacy, and patient preference...
  63. ncbi Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy
    Paul D Williams
    Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia 22908, USA
    Cancer Res 69:8302-9. 2009
    ..Use of such in vitro-based GEMs may provide a robust and generalizable approach to personalized cancer therapy...
  64. ncbi Status of robotic cystectomy in 2005
    Nicole L Miller
    Department of Urology, Methodist Hospital Institute for Kidney Stone Disease and Indiana University School of Medicine, 1801 N Senate Blvd, Suite 220, Indianapolis, 46202, USA
    World J Urol 24:180-7. 2006
    ..We review the current experience with laparoscopic and robotic radical cystectomy and its role in the treatment of muscle invasive bladder cancer...
  65. ncbi A novel method for gene expression mapping of metastatic competence in human bladder cancer
    Z Wu
    Department of Molecular Physiology, Box 422, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA
    Neoplasia 8:181-9. 2006
    ..In summary, we show that gene expression changes during bladder cancer lung metastasis occur nonrandomly in specific chromosomes and intrachromosomal locations...
  66. ncbi Molecular therapeutics in prostate cancer
    B Nicholson
    University of Virginia, Department ot Urology, P.O. Box 800422, Charlottesville, Virginia 22908, USA
    Histol Histopathol 18:275-98. 2003
    ....
  67. ncbi The effect of sampling more cores on the predictive accuracy of pathological grade and tumour distribution in the prostate biopsy
    A A Makhlouf
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    BJU Int 93:271-4. 2004
    ..CONCLUSION: Taking > or = 8 biopsy cores improved the pathological grading accuracy, which may be valuable in choosing a treatment for the patient with newly diagnosed prostate cancer...
  68. ncbi Permanent interstitial brachytherapy for prostate cancer: a current review
    Jeffrey Woolsey
    Department of Urology, University of Virginia Health Sciences Center, Box 422, Charlottesville, VA 22908, USA
    World J Urol 21:209-19. 2003
    ..Results will be discussed both in terms of cancer control and health-related quality of life endpoints...
  69. ncbi Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC)
    COURTNEY POLLARD
    Department of Molecular Physiology, University of Virginia, Charlottesville, VA 22908, USA
    Expert Rev Mol Med 12:e10. 2010
    ..Since several of these driving changes are amenable to therapeutic targeting, understanding the signalling events in NMIUC may offer novel approaches to manage the recurrence and progression of this disease...
  70. ncbi The role of Ras superfamily proteins in bladder cancer progression
    Gary Oxford
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville, VA, USA
    J Urol 170:1987-93. 2003
    ..CONCLUSIONS: The findings discussed offer the hopeful possibility that signaling pathways mediated by Ras superfamily members may offer new opportunities for diagnostic and therapeutic interventions in bladder cancer...
  71. ncbi Ras superfamily monomeric G proteins in carcinoma cell motility
    Gary Oxford
    Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908, USA
    Cancer Lett 189:117-28. 2003
    ..Novel emerging mechanisms of migration in carcinoma cells involving RhoC and Ral are also discussed...
  72. ncbi The Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic target
    Steven Christopher Smith
    Department of Urology, Molecular Physiology, Biological Physics, University of Virginia Health System, Charlottesville, VA 22908, USA
    Urol Oncol 27:42-7. 2009
    ..These findings are reviewed here and suggest that Ral GTPases and their downstream pathways constitute key mediators of bladder cancer progression and may include targets for future therapeutic strategies...
  73. ncbi Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases
    Konstadinos Moissoglu
    Robert M Berne Cardiovascular Research Center, University of Virginia, Charlottesville, Virginia 22908, USA
    Cancer Res 69:2838-44. 2009
    ..These data show that RhoGDI2 metastasis inhibition works through Rho GTPases but via a mechanism distinct from inhibition of membrane association...
  74. ncbi Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model
    Jill K Slack-Davis
    Department of Microbiology, University of Virginia, Charlottesville, Virginia 22908, USA
    Mol Cancer Ther 8:2470-7. 2009
    ....
  75. ncbi Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading?
    Emily B Smith
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Cancer 94:2282-7. 2002
    ..Therefore, outcome studies including a biopsy Gleason score from older specimens as a risk variable have a significant chance of being vulnerable to this phenomenon. Based on the authors' data, all such specimens should undergo rereview...
  76. ncbi Rap2 regulates androgen sensitivity in human prostate cancer cells
    Dora Bigler
    Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Prostate 67:1590-9. 2007
    ..Here we ask if Rap proteins play a role in determining androgen sensitivity of human prostate cancer cells either alone or in the context of an activated Ras...
  77. ncbi A novel model to identify interaction partners of the PTEN tumor suppressor gene in human bladder cancer
    Mikael Herlevsen
    Department of Molecular Physiology, University of Virginia, Charlottesville, VA 22908, USA
    Biochem Biophys Res Commun 352:549-55. 2007
    ..In conclusion, using a biologically relevant model system to dissect PTEN tumor suppressor function in human bladder cancer, we identified three molecules important for many cellular functions in complex with PTEN...
  78. ncbi The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer
    Steven C Smith
    Department of Molecular Physiology, University of Virginia, Charlottesville, Virginia, USA
    Cancer Res 66:1917-22. 2006
    ..We suggest that these insights may lead to future therapeutic approaches that seek to eliminate CD24 function in cancer cells...
  79. ncbi Prospective outcomes associated with migration from preoperative to intraoperative planned brachytherapy: a single center report
    Jeffrey Woolsey
    Departments of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia, USA
    J Urol 172:2528-31. 2004
    ..In addition, the approach is not associated with any changes in early postoperative voiding symptoms and, due to only marginally longer operative times, may have a cost advantage by eliminating the preplanning visit and ultrasound...
  80. ncbi Radical cystectomy with ileal conduit diversion: early prospective evaluation of the impact of robotic assistance
    Jonathan J Rhee
    Department of Urology, University of Virginia, Charlottesville, VA 22908, USA
    BJU Int 98:1059-63. 2006
    ..There was no difference in patient BMI between the groups (P = 0.22). CONCLUSION: The daVinci-assisted cystectomy appears to offer some advantages over standard cystectomy. Larger randomized studies are needed to confirm these findings...
  81. ncbi PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity
    John J Gildea
    Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Box 422, Charlottesville, VA 22908, USA
    Oncogene 23:6788-97. 2004
    ....
  82. ncbi Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer
    Sophie G Fletcher
    Department of Urology, University of Virginia Health System, Charlottesville, VA 22908, USA
    Int J Radiat Oncol Biol Phys 66:1092-9. 2006
    ..44 (0.26-0.74; p = 0.002). CONCLUSIONS: High-risk prostate cancer patients receiving multimodality radiation therapy (BTC) display apparently superior BFS compared with those receiving surgery (RP) or brachytherapy alone (BTM)...
  83. ncbi Molecular pathogenesis of urothelial bladder cancer
    D Theodorescu
    University of Virginia, Department of Urology, P O Box 800422, Charlottesville, Virginia 22908, USA
    Histol Histopathol 18:259-74. 2003
    ..The intent of this review is to provide the reader an overview of our current understanding of this tumor from the standpoint of its molecular biology as related to tumor development and progression...
  84. ncbi Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients
    T R Coblentz
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Prostate Cancer Prostatic Dis 5:219-25. 2002
    ..Clearly, longer follow-up is required to confirm the durability of this approach...
  85. ncbi Cancer incidence after localized therapy for prostate cancer
    Kihyuck Moon
    Department of Urology, University of Virginia, Charlottesville, Virginia 22908, USA
    Cancer 107:991-8. 2006
    ..It is noteworthy that, to the authors' knowledge, this report shows for the first time that, despite the higher doses of radiation delivered, patients who received radioactive implants had the lowest odds of developing second cancers...
  86. ncbi Unusual case of recurrent low-grade invasive and endophytic squamous cell carcinoma of the penis
    Caroline D Ames
    Department of Urology, University of Virginia, Charlottesville, VA, USA
    Scand J Urol Nephrol 38:258-9. 2004
    ..We present a case of low-grade yet recurrent and invasive squamous cell carcinoma that may constitute a new biological variant of penile cancer...
  87. ncbi Morbidity of modified prophylactic inguinal lymphadenectomy for squamous cell carcinoma of the penis
    Timothy R Coblentz
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville, 22908, USA
    J Urol 168:1386-9. 2002
    ..Early followup indicates that the local recurrence rate does not appear to increase compared to similar patients reported on in the literature treated with the classic dissection technique...
  88. ncbi Mass spectrometry based proteomics in urine biomarker discovery
    Dan Theodorescu
    Department of Molecular Physiology, University of Virginia, Charlottesville, USA
    World J Urol 25:435-43. 2007
    ..The second part summarizes the recent progress in the definition and identification of clinically relevant polypeptide markers...
  89. ncbi Expression of ral GTPases, their effectors, and activators in human bladder cancer
    Steven Christopher Smith
    Department of Molecular Physiology, University of Virginia, Charlottesville, Virginia 22908, USA
    Clin Cancer Res 13:3803-13. 2007
    ....
  90. ncbi Brachytherapy of prostate cancer after colectomy for colorectal cancer: pilot experience
    Panos G Koutrouvelis
    URO Radiology Prostate Institute, 8320 Old Courthouse Road, Vienna, Virginia 22182, USA
    J Urol 173:82-5; discussion 85-6. 2005
    ..We present a method of brachytherapy for prostate cancer using a 3-dimensional stereotactic system and computerized tomography guidance in patients without a rectum due to previous treatment for colorectal cancer...
  91. ncbi Statistical identification of differentially labeled peptides from liquid chromatography tandem mass spectrometry
    HyungJun Cho
    Department of Statistics, Korea University, Seoul, Korea
    Proteomics 7:3681-92. 2007
    ....
  92. ncbi Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach
    Brian Nicholson
    Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia, USA
    Clin Cancer Res 10:8728-34. 2004
    ..Increased necrosis observed in tumors from orchiectomized mice receiving ZD6474 also suggests benefit from combining anti-androgen and anti-VEGF signaling approaches...
  93. ncbi Adrenal tumor with caval extension--case report and review of the literature
    John P Chesson
    Department of Urology, University of Virginia Health Sciences Center, Charlottesville 22908, USA
    Scand J Urol Nephrol 36:71-3. 2002
    ..Our review suggests that over half of all adrenal lesions with IVC extension will be clinically nonfunctional, including up to 17% of pheochromocytomas...
  94. ncbi Angiogenesis and prostate cancer tumor growth
    Brian Nicholson
    Department of Urology, University of Virginia, Charlottesville, Virginia 22908-0422, USA
    J Cell Biochem 91:125-50. 2004
    ..This review discusses angiogenesis mediators, and the potential for manipulation of angiogenic factors as a practical cancer therapy, particularly in prostate cancer...
  95. ncbi Profiling the evolution of human metastatic bladder cancer
    Brian E Nicholson
    Department of Molecular Physiology and Biological Physics, Division of Biostatistics, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Cancer Res 64:7813-21. 2004
    ....
  96. ncbi The role of Ral A in epidermal growth factor receptor-regulated cell motility
    John J Gildea
    Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Cancer Res 62:982-5. 2002
    ..This is the first demonstration of an essential role for Ral in EGF-mediated cell motility and its potential contribution to tumor metastasis in human cancer...
  97. ncbi Metastasis: a therapeutic target for cancer
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Nat Clin Pract Oncol 5:206-19. 2008
    ..Here we discuss the similarity and differences between primary tumors and metastases, pathways controlling the colonization of a distant organ, and incorporation of antimetastatic therapies into clinical testing...
  98. ncbi Longitudinal comparison of sexual function after 3-dimensional conformal radiation therapy or prostate brachytherapy
    Richard K Valicenti
    Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    J Urol 168:2499-504; discussion 2504. 2002
    ..Longer followup will be needed to evaluate this hypothesis...
  99. ncbi Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application
    Carrie W Rinker-Schaeffer
    Section of Urology, Department of Surgery, The University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 12:3882-9. 2006
  100. ncbi Isolation and identification of potential urinary microparticle biomarkers of bladder cancer
    David M Smalley
    Mellon Medical Biomarker Discovery Laboratory, W M Keck Laboratory for Mass Spectrometry, Department of Urology, University of Virginia, Charlottesville, Virginia 22908, USA
    J Proteome Res 7:2088-96. 2008
    ..Further studies will be needed to validate these potential biomarkers...